收费全文 | 4500689篇 |
免费 | 319866篇 |
国内免费 | 10280篇 |
耳鼻咽喉 | 63856篇 |
儿科学 | 145961篇 |
妇产科学 | 124518篇 |
基础医学 | 642023篇 |
口腔科学 | 128246篇 |
临床医学 | 415927篇 |
内科学 | 858195篇 |
皮肤病学 | 102469篇 |
神经病学 | 365416篇 |
特种医学 | 170051篇 |
外国民族医学 | 1290篇 |
外科学 | 671631篇 |
综合类 | 99102篇 |
现状与发展 | 16篇 |
一般理论 | 1856篇 |
预防医学 | 358720篇 |
眼科学 | 106418篇 |
药学 | 331537篇 |
18篇 | |
中国医学 | 8854篇 |
肿瘤学 | 234731篇 |
2018年 | 49423篇 |
2017年 | 37684篇 |
2016年 | 43085篇 |
2015年 | 48622篇 |
2014年 | 68234篇 |
2013年 | 103702篇 |
2012年 | 139326篇 |
2011年 | 147946篇 |
2010年 | 88786篇 |
2009年 | 84164篇 |
2008年 | 138051篇 |
2007年 | 147003篇 |
2006年 | 148642篇 |
2005年 | 143836篇 |
2004年 | 138461篇 |
2003年 | 133520篇 |
2002年 | 128888篇 |
2001年 | 196670篇 |
2000年 | 201664篇 |
1999年 | 171168篇 |
1998年 | 52258篇 |
1997年 | 45847篇 |
1996年 | 45606篇 |
1995年 | 43695篇 |
1994年 | 40264篇 |
1993年 | 37950篇 |
1992年 | 135774篇 |
1991年 | 132111篇 |
1990年 | 128698篇 |
1989年 | 124815篇 |
1988年 | 115308篇 |
1987年 | 113159篇 |
1986年 | 106892篇 |
1985年 | 102704篇 |
1984年 | 77342篇 |
1983年 | 66159篇 |
1982年 | 39893篇 |
1981年 | 36065篇 |
1979年 | 71849篇 |
1978年 | 51369篇 |
1977年 | 43463篇 |
1976年 | 40934篇 |
1975年 | 43971篇 |
1974年 | 52814篇 |
1973年 | 50427篇 |
1972年 | 47789篇 |
1971年 | 44711篇 |
1970年 | 41480篇 |
1969年 | 40040篇 |
1968年 | 36774篇 |
Background
Nursing Home Compare (NHC) ratings, created and maintained by Medicare, are used by both hospitals and consumers to aid in the skilled nursing facility (SNF) selection process. To date, no studies have linked NHC ratings to actual episode-based outcomes. The purpose of this study was to evaluate whether NHC ratings are valid predictors of 90-day complications, readmission, and bundle costs for patients discharged to an SNF after primary total joint arthroplasty (TJA).Methods
All SNF-discharged primary TJA cases in 2017 at a multihospital academic health system were queried. Demographic, psychosocial, and clinical variables were manually extracted from the health record. Medicare NHC ratings were then collected for each SNF. For patients in the Medicare bundle, postacute and total bundle cost was extracted from claims.Results
Four hundred eighty-eight patients were discharged to a total of 105 unique SNFs. In multivariate analysis, overall NHC rating was not predictive of 90-day readmission/major complications, >75th percentile postacute cost, or 90-day bundle cost exceeding the target price. SNF health inspection and quality measure ratings were also not predictive of 90-day readmission/major complications or bundle performance. A higher SNF staffing rating was independently associated with a decreased odds for >75th percentile 90-day postacute spend (odds ratio, 0.58; P = .01) and a 90-day bundle cost exceeding the target price (odds ratio = 0.69; P = .02) but was similarly not predictive of 90-day readmission/complications.Conclusion
Results of our study suggest that Medicare's NHC tool is not a useful predictor of 90-day costs, complications, or readmissions for SNFs within our health system. 相似文献Areas covered: the principal pharmacogenetic and non-genetic differences in the pharmacology of tamoxifen and endoxifen are evaluated. To this end, references from PubMed, Embase or Web of Science, among others, were reviewed As non-genetic factors, important differences and similarities such age, or adherence to tamoxifen therapy are comprehensively illustrated. Additionally, since CYP2D6 genotypes are considered the main limitation of tamoxifen, many studies have investigated the association between the worsened clinical outcomes in patients with non-functional CYP2D6 genotypes. In this review, an overview of the research on this field is presented. Also, a summary describing the literature about individualizing tamoxifen therapy with endoxifen concentrations and its limitations is listed.
Expert opinion: z-endoxifen hydrochloride is only investigated in the metastatic setting, still more research is required before its place in therapeutics is known. Similarly, monitoring tamoxifen efficacy based on endoxifen concentrations might not be overall recommended due to the limited evidence available. 相似文献
Areas covered: This review focuses on current treatments and the future outlook for allergic rhinitis. Pharmacotherapy includes mast cell stabilizers, antihistamines, glucocorticosteroids (GCSs), leukotriene receptor antagonists, and nasal decongestants. Nasal GCSs are currently regarded as the most effective treatment and are considered first-line therapy together with non-sedating antihistamines. The new formulation MP29-02 combines the nasal GCS fluticasone propionate with azelastine in one single spray and has achieved greater improvements than those under monotherapy with modern GCSs or antihistamines. Furthermore, this review discusses allergen immunotherapy alone and in combination with modern monoclonal antibodies.
Expert opinion: Despite the variety of medications for allergic rhinitis, ranging from general symptomatic agents like GCSs or decongestants, to more specific ones like histamine receptor or leukotriene blockers, to causal therapy like immunotherapy, many patients still experience treatment failures or unsatisfactory results. The ultimate goal may be to endotype every downstream pathway separately in order to offer patients individualized, targeted therapy with specific antibodies against the respective pathway. 相似文献